Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Helene Helfer"'
Autor:
Samaher Besbes, Shahid Shah, Iman Al-dybiat, Shahsoltan Mirshahi, Helene Helfer, Haythem Najah, Caroline Fourgeaud, Marc Pocard, Ibtissem Ghedira, Jeannette Soria, Massoud Mirshahi
Publikováno v:
International Journal of Cell Biology, Vol 2017 (2017)
The thrombopoietin (TPO) gene expression in human ovary and cancer cells from patients with ovarian carcinomatosis, as well as several cancer cell lines including MDA-MB231 (breast cancer), K562 and HL60 (Leukemic cells), OVCAR-3NIH and SKOV-3 (ovari
Externí odkaz:
https://doaj.org/article/885b50de48f444b1a7b565548f3c46c7
Autor:
Géraldine Poénou, Emmanuel Tolédano, Hélène Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, Isabelle Mahé
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
IntroductionAnticoagulant is the cornerstone of the management of VTE at the cost of a non-negligible risk of bleeding. Reliable and validated clinical tools to predict thromboembolic and hemorrhagic events are crucial for individualized decision-mak
Externí odkaz:
https://doaj.org/article/7f100e4aa648408bbf1ec0e6a5c498db
Autor:
Hélène Helfer, Yara Skaff, Florent Happe, Sadji Djennaoui, Jean Chidiac, Géraldine Poénou, Marc Righini, Isabelle Mahé
Publikováno v:
Cancers, Vol 15, Iss 11, p 3031 (2023)
Venous thromboembolic disease (VTE) is a common complication in cancer patients. The currently recommended VTE diagnostic approach involves a step-by-step algorithm, which is based on the assessment of clinical probability, D-dimer measurement, and/o
Externí odkaz:
https://doaj.org/article/3b034b92eac84a7f8abe29148020a92b
Autor:
Géraldine Poénou, Emmanuel Tolédano, Hélène Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, Isabelle Mahé
Publikováno v:
Cancers, Vol 14, Iss 8, p 1937 (2022)
Patients with venous thromboembolism events (VTE) in the context of cancer should receive anticoagulants as long as the cancer is active. Therefore, a tailor-made anticoagulation strategy should rely on an individualized risk assessment model (RAM) o
Externí odkaz:
https://doaj.org/article/355a683846e74b7fa55e4e27a9b59f23
Autor:
Isabelle Mahé, Ludovic Plaisance, Céline Chapelle, Silvy Laporte, Benjamin Planquette, Laurent Bertoletti, Francis Couturaud, Nicolas Falvo, Lionel Falchero, Isild Mahé, Hélène Helfer, Jean Chidiac, Guy Meyer
Publikováno v:
Cancers, Vol 12, Iss 8, p 2256 (2020)
Background: extended anticoagulant therapy beyond the initial 6 months is suggested in patients with cancer-associated thrombosis (CAT) and active cancer. Few data are available on patient management and outcomes on the period between 6 and 12 months
Externí odkaz:
https://doaj.org/article/66726b333f1742f7912c02261b76e4ae